DLL3-Targeted Therapies: Transforming the Future of Oncology

σε πρόσθεσε στο Health

2025-11-14 12:01:46

Delta-like ligand 3 (DLL3) has become a key focus in oncology, particularly for treating neuroendocrine tumors such as small cell lung cancer (SCLC). Over the past decade, DLL3-targeted Therapies Market developments have gained attention for their potential to address unmet clinical needs and improve patient outcomes. By targeting DLL3, which is overexpressed in certain tumor cells while...

0 Σχόλια 0 Μοιράστηκε 44 Views 0 Προεπισκόπηση